New pages
Jump to navigation
Jump to search
- 13:22, 4 March 2024 Pyruvate kinase deficiency (hist | edit) [708 bytes] Jwarner (talk | contribs) (Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...")
- 02:02, 20 January 2024 Oblimersen (Genasense) (hist | edit) [763 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oblimersen-sodium NCI Drug Dictionary]: The sodium salt of a phosphorothioat...")
- 15:41, 19 January 2024 Eflornithine (Iwilfin) (hist | edit) [1,090 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/eflornithine-hydrochloride NCI Drug Dictionary]: A difluoromethylated ornith...")
- 01:24, 19 January 2024 Danicopan (ALXN-2040) (hist | edit) [1,017 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== Complement factor D inhibitor ==Preliminary data== ===Paroxysmal nocturnal hemoglobinuria (PNH)=== #'''ALPHA:'...")
- 18:05, 18 January 2024 Tarlatamab (AMG-757) (hist | edit) [1,644 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the NCI Drug Dictionary: A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against...")
- 03:33, 30 December 2023 Hypereosinophilic syndrome - null regimens (hist | edit) [3,313 bytes] Jwarner (talk | contribs) (Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development o...")
- 13:58, 20 December 2023 Repotrectinib (Augtyro) (hist | edit) [2,205 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/repotrectinib NCI Drug Dictionary]: An orally available inhi...")